RATG reduces risk of pediatric kidney graft thrombosis by decreasing platelet count

This article has no abstract so we have provided the first paragraph of the full text.

Thrombosis is a major cause of early graft failure in pediatric kidney transplant recipients. Rabbit antithymocyte globulin (RATG), which lowers platelet count, is commonly used as induction immunotherapy and to treat steroid-resistant rejection. As platelets are an important factor in vascular thrombosis formation, Kamel et al. investigated whether RATG therapy reduces the risk of graft thrombosis in pediatric kidney transplant recipients.

ARTICLE NAVIGATION - ARTICLE TOOLS

• Full text
• Download PDF
• Send to a friend
• PDA services
• Permissions

ISSUE NAVIGATION - THIS ISSUE

• Table of Contents
• Previous article
• Next article